Resources Repository
-
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
Health/Medicine | Business/Industry | Economics/Finance | Infectious Diseases | Mathematical Models | State-Transition | Benefit-Cost Analysis | Policy/Regulation | Government/Law | North America -
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Health/Medicine | Business/Industry | Economics/Finance | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Evidence Synthesis | Value of Information | Cost-Effectiveness Analysis | Technology Assessment | Chronic Disease/Risk | Mental Health | Health Systems | Government/Law | Science/Technology | North America | Europe -
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Health/Medicine | Business/Industry | Economics/Finance | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Outcomes | Value of Information | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Operations Research | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Science/Technology | Global -
OrganizationWeb Portal 2024Immunization Costing Action Network (ICAN)
The Immunization Costing Action Network (ICAN) aims to increase the availability, understanding, and use of …
The Immunization Costing Action Network (ICAN) aims to increase the availability, understanding, and use of immunization delivery cost information. They are building country capacity around the generation of cost information to solve program and policy challenges and working with countries to improve interpretation and translation of cost information for country decision-making processes and routine planning and budgeting. The ICAN is comprised of four-member countries (India, Indonesia, Tanzania, and Vietnam) with country teams that include health…
Health/Medicine | Business/Industry | Economics/Finance | Infectious Diseases | Costing Methods | Child/Nutrition | Health Systems | Science/Technology | Global -
ArticlePublication 2023Cost-Effectiveness of Novel TB Vaccines: A Modeling Study
A modeling study assessed future costs, cost-savings, and cost-effectiveness of introducing novel tuberculosis (TB) vaccines …
A modeling study assessed future costs, cost-savings, and cost-effectiveness of introducing novel tuberculosis (TB) vaccines in 105 low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies, compared to a ‘no-new-vaccine’ counterfactual. Vaccine scenarios considered two vaccine product profiles (one targeted at infants, one at adolescents/adults), both assumed to prevent progression to active TB. Vaccine introduction was estimated to require substantial near-term resources, offset by future cost-savings from averted TB burden.…
Health/Medicine | Economics/Finance | Infectious Diseases | Mathematical Models | Cost-Effectiveness Analysis | Global -
ArticlePublication 2022Comparative Health Systems Analysis of Differences in Catastrophic Health Expenditure
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications …
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications for health system performance in the area of financial risk protection, as measured by catastrophic health expenditure (CHE). This article compares non-communicable diseases catastrophic health expenditure to the CHE cases caused by communicable diseases across health systems to examine whether: (1) disease burden and catastrophic health expenditure are linked, (2) Catastrophic health expenditures secondary to NCDs disproportionately affect wealthier households and (3) whether the drivers…
Health/Medicine | Economics/Finance | Infectious Diseases | Costing Methods | Evidence Synthesis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Global -
ArticlePublication 2022Vaccinations versus Lockdowns to Prevent COVID-19 Mortality
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly …
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly available datasets from the Israeli Ministry of Health were used to model the parameters of the pandemic in Israel. The Oxford COVID-19 Government Response Tracker was used for quantitative data on government policies. Data on the Israeli economy were taken from the Central Bureau of Statistics. The models demonstrate that the first lockdown prevented 1022 COVID-19 deaths at the cost…
Health/Medicine | Economics/Finance | Infectious Diseases | Decision Theory | Costing Methods | Health Outcomes | State-Transition | Decision Analysis | Policy/Regulation | Government/Law | Middle East & North Africa -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Health/Medicine | Economics/Finance | Infectious Diseases | Priority Setting/Ethics | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Policy/Regulation | Global | North America -
ArticlePublication 2017Catastrophic Costs Potentially Averted by TB Control in India and South Africa
This study estimated the reduction in tuberculosis-related catastrophic costs with an aggressive expansion of tuberculosis …
This study estimated the reduction in tuberculosis-related catastrophic costs with an aggressive expansion of tuberculosis services in India and South Africa from 2016 to 2035, in line with the End TB Strategy. The authors investigated three intervention scenarios: improved treatment of drug-sensitive tuberculosis; improved treatment of multidrug-resistant tuberculosis; and expansion of access to tuberculosis care through intensified case finding (South Africa only). In India and South Africa, improvements in treatment for drug-sensitive and multidrug-resistant tuberculosis…
Health/Medicine | Economics/Finance | Infectious Diseases | Priority Setting/Ethics | Mathematical Models | Health Systems | Sub-Saharan Africa | Asia & Pacific